Date: 2016-01-08
Type of information: Nomination
Compound:
Company: Immatics Biotechnologies (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 8, 2016, Immatics Biotechnologies announced the appointment of Katina Dorton as Chief Financial Officer (CFO), effective immediately. Katina brings more than 20 years’ of experience in investment banking and has served as a senior strategic advisor to numerous companies in the life sciences, medical devices and healthcare sectors. She is a former Managing Director Investment Banking, Morgan Stanley in New York and Frankfurt, Germany, serving 12 years at the firm. She later was Managing Director, Life Sciences, at Needham & Co. Prior to her investment banking career Dorton practiced law in mergers and acquisitions at Sullivan & Cromwell.
Katina’s has deep expertise in corporate finance, capital raising and M&A, having led the execution of over 60 completed financing transactions raising more than $50 billion in equity and debt, including 25 IPOs and advised on dozens of M&A transactions. Katina holds BA in Economics from Duke University, an MBA from George Washington University and a JD from the University of Virginia.
Financial terms:
Latest news:
